Prosecutors say Regeneron ran an Eylea racket
There’s nothing to stop drug companies from pouring money into charities that end up paying patients’ co-pays. What they can’t do is specify that those charities only cover certain drugs. And that, according to federal prosecutors, is exactly what Regeneron Pharmaceuticals did.
As STAT’s Ed Silverman reports, Regeneron is accused of paying tens of millions of dollars to the Chronic Disease Fund under the guarantee that its money would only go toward co-pays for Eylea, the company’s injectable treatment for macular degeneration. That helped Regeneron stave off competition, according to authorities. Regeneron denies the allegations.
This is hardly the first time a drug company has been accused of using a patient charity as a commercial crutch. Over the past two years alone, drug makers including Novartis, Alexion Pharmaceuticals, and Pfizer have settled similar allegations with the government.
Read more.
As STAT’s Ed Silverman reports, Regeneron is accused of paying tens of millions of dollars to the Chronic Disease Fund under the guarantee that its money would only go toward co-pays for Eylea, the company’s injectable treatment for macular degeneration. That helped Regeneron stave off competition, according to authorities. Regeneron denies the allegations.
This is hardly the first time a drug company has been accused of using a patient charity as a commercial crutch. Over the past two years alone, drug makers including Novartis, Alexion Pharmaceuticals, and Pfizer have settled similar allegations with the government.
Read more.
No hay comentarios:
Publicar un comentario